Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Issuers will hope the outperformance continues, as consensus is now that there will be no EPS growth in Q1. Bank of America ...

PTC Therapeutics Inc (PTCT) surpasses revenue expectations, strengthens cash position, and prepares for multiple product ...

Cash burn is likely to moderate going forward, as investments in Schrödinger's internal pipeline have now stabilized. Read ...

Despite a decline in total revenue, Schrodinger Inc (SDGR) showcases robust software performance and strategic collaborations ...

Reports Q4 revenue $88.3M, consensus $83.2M. “We are delighted with Schrodinger’s (SDGR) excellent financial performance in 2024. Software ...

Q4 2024 Earnings Call Transcript February 26, 2025 Standard BioTools Inc. misses on earnings expectations. Reported EPS is $-0.09097 EPS, expectations were $-0.07. Operator: Good day, everyone, and ...

I was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was – did the company have any designs on entering the viral vector-based gene therapy ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...